Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14017644 | 0.80 | HRH3 (0.34) | HRH3L3MBTL3L3MBTL1ARG1ARG2 | |
| SCHEMBL2158111 | 0.79 | HRH3 (0.36) | HRH3L3MBTL3L3MBTL1HPGDKMT2A | |
| SCHEMBL13432054 | 0.78 | ALDH1A1 (0.37) | HRH3ESR2L3MBTL3L3MBTL1KMT2A | |
| SCHEMBL17692977 | 0.73 | HRH3 (0.39) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL15710120 | 0.72 | HRH3 (0.34) | HRH3L3MBTL3L3MBTL1HPGDKMT2A | |
| SCHEMBL15710119 | 0.72 | HRH3 (0.34) | HRH3L3MBTL3L3MBTL1HPGDKMT2A | |
| SCHEMBL13381568 | 0.72 | CYP2D6 (0.40) | HRH3L3MBTL3L3MBTL1HPGDKMT2A | |
| SCHEMBL4481058 | 0.72 | HRH3 (0.34) | HRH3L3MBTL3L3MBTL1HPGDKMT2A | |
| SCHEMBL521969 | 0.72 | HRH3 (0.39) | HRH3L3MBTL3L3MBTL1HPGDKMT2A | |
| SCHEMBL31306492 | 0.72 | GBA1 (0.36) | HRH3L3MBTL3L3MBTL1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696195-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7696195-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7696195-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| EP-1992349-A1 | CGRP antagonists, their preparation and use as a medicament | Boehringer Ingelheim International GmbH (DE) | 2008-11-19 | — | — | EP | disclosed |
| EP-1863791-B1 | 2-OXO-1,2,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-3-YL-PIPERIDINES USED AS CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2008-11-12 | — | — | EP | disclosed |
| EP-1740577-A2 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | disclosed |
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005103037-A2 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | HRH3 160/4885ESR2 1508/4885L3MBTL3 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.